Kronos Bio
KRON
KRON was delisted on the 20th of June, 2025.
96 hedge funds and large institutions have $282M invested in Kronos Bio in 2022 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 24 increasing their positions, 32 reducing their positions, and 5 closing their positions.
50,600% more call options, than puts
Call options by funds: $1.01M | Put options by funds: $2K
300% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 5
19% more funds holding
Funds holding: 81 → 96 (+15)
3.95% less ownership
Funds ownership: 72.84% → 68.9% (-3.9%)
25% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 32
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
49% less capital invested
Capital invested by funds: $558M → $282M (-$276M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$9.58M |
| 2 |
State Street
Boston,
Massachusetts
|
+$3.84M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.92M |
| 4 |
Renaissance Technologies
New York
|
+$1.49M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$10.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.67M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$8.15M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6.74M |
| 5 |
CC
Commodore Capital
New York
|
-$4.06M |
KRON Hedge Fund Activity: Q1 2022 in Review
96 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Kronos Bio (KRON) for Q1 2022, worth a combined $282M — down 49% from $558M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new KRON positions and 5 closed out — a net gain of 15 holders — while 24 added to existing stakes and 32 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $9.58M. The largest seller was Victory Capital Management, cutting an estimated $10.1M.
- 96 institutional investors held Kronos Bio (KRON) as of Q1 2022, up from 81 in Q4 2021.
- Funds reported $282M of Kronos Bio stock for Q1 2022, down 49% quarter-over-quarter.
- 20 funds opened new Kronos Bio positions in Q1 2022 and 5 closed out, a net change of +15 holders.
- The largest Kronos Bio buyer in Q1 2022 was JP Morgan Chase, an estimated $9.58M added.
- The largest Kronos Bio seller in Q1 2022 was Victory Capital Management, an estimated $10.1M sold.
Based on aggregated 13F filings for Q1 2022.